Galvus Met 50 mg + 850 mg

Type 2 diabetes mellitus in adults not adequately controlled by metformin or vildagliptin alone, or already treated with both drugs as separate tablets.

Vildagliptin raises incretin hormone levels by inhibiting DPP-4, increasing insulin release and lowering glucagon; metformin reduces glucose production in the liver and improves insulin sensitivity. The two complementary actions improve blood glucose control.

Adult: one tablet twice daily, morning and evening, with or just after food. The strength (50 mg + 500 mg, 50 mg + 850 mg or 50 mg + 1000 mg) is chosen according to the current metformin dose; maximum vildagliptin 100 mg daily.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, dizziness, headache and tremor. Liver dysfunction, pancreatitis and lactic acidosis are rare.

Check kidney and liver function before and during treatment. Stop temporarily before iodinated contrast examinations or major surgery and during severe infection or dehydration. Avoid excessive alcohol.

Severe renal impairment, hepatic impairment, diabetic ketoacidosis or other metabolic acidosis, conditions causing tissue hypoxia, alcoholism, pregnancy, breast-feeding and hypersensitivity to either component.

Store below 30°C in a cool, dry place, away from light. Keep out of the reach of children.